Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Hepatol. Nov 27, 2021; 13(11): 1766-1776
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1766
Table 1 Demographic characteristics and comorbidities of patients with newly diagnosed peripartum primary liver cancer in Taiwan during 1996-2012
Characteristics
Total, NPeripartum primary liver cancer
P value
No, n = 160
Yes, n = 40
n (%) / mean ± SD
n (%) / mean ± SD
Age0.788
< 308869 (43.1)19 (47.5)
30-346453 (33.1)11 (27.5)
35-494838 (23.8)10 (25)
mean ± SD131.3 ± 5.130.9 ± 4.80.673
Baseline comorbidity
HBV5847 (29.4)11 (27.5)0.815
Unspecified chronic hepatitis21 (0.6)1 (2.5)0.286
Alcoholic liver disease65 (3.1)1 (2.5)0.836
Cirrhosis96 (3.8)3 (7.5)0.306
Biliary stone64 (2.5)2 (5)0.407
Cholecystitis128 (5)4 (10)0.234
Cholangitis107 (4.4)3 (7.5)0.417
Table 2 Cox model measured hazard ratios and 95% confidence intervals of death associated non-peripartum primary liver cancer and peripartum primary liver cancer patients
Characteristics
Event, n = 124Person, yrIR
Crude
Adjusted
HR (95%CI)
P value
HR (95%CI)
P value
Peripartum primary liver cancer
No9758716.53Ref.Ref.
Yes279927.171.35 (0.88-2.08)0.1661.40 (0.89-2.20)0.149
Age at baseline
< 305435015.44Ref.Ref.
30-343916923.081.21 (0.80-1.84)0.3591.47 (0.95-2.28)0.083
35-493116718.521.29 (0.83-2.00)0.2661.13 (0.69-1.85)0.617
Baseline comorbidity
HBV2723011.720.52 (0.34-0.80)0.0030.48 (0.30-0.77)0.002
Unspecified chronic hepatitis1119.040.86 (0.12-6.17)0.8820.56 (0.08-4.10)0.565
Alcoholic liver disease6873.372.85 (1.25-6.49)0.0132.15 (0.73-6.36)0.165
Cirrhosis74017.551.12 (0.52-2.40)0.7731.49 (0.57-3.90)0.411
Biliary stone41135.471.23 (0.45-3.33)0.6860.64 (0.17-2.35)0.499
Cholecystitis5806.260.43 (0.18-1.06)0.0660.30 (0.12-0.75)0.010
Cholangitis74179.303.76 (1.71-8.26)< 0.0013.34 (1.49-7.47)0.003
Table 3 Survival rates of different follow-up durations between non-peripartum primary liver cancer and peripartum primary liver cancer patients
Follow-up durationSurvival rate (%)
P value
Non-peripartum primary liver cancer
Peripartum primary liver cancer
≤ 0.578.9471.790.254
≤ 163.6160.840.611
≤ 344.8530.420.111
≤ 539.5927.380.117
Table 4 Demographic characteristics and comorbidities of female patients newly diagnosed with and without menopause primary liver cancer patients in Taiwan during 1996-2012
Characteristics
Total, N = 13440Liver cancer
P value
≥ 50 yr, n = 10752
< 50 yr, n = 2688
n (%)/mean ± SD
n (%)/mean ± SD
Age
mean ± SD169.1 ± 9.639.7 ± 10.5< 0.001
Baseline comorbidity
HBV29712358 (21.9)613 (22.8)0.329
HCV1168931 (8.7)237 (8.8)0.795
Unspecified chronic hepatitis780619 (5.8)161 (6)0.645
Alcoholic liver disease211157 (1.5)54 (2)0.041
Cirrhosis41423321 (30.9)821 (30.5)0.730
Biliary stone12691012 (9.4)257 (9.6)0.813
Cholecystitis626489 (4.5)137 (5.1)0.227
Cholangitis818649 (6)169 (6.3)0.626
Table 5 Cox model measured hazard ratios and 95% confidence intervals of death associated with and without menopause primary liver cancer patients
Characteristics
Event, N = 9982Person, yrIR
Crude
Adjusted
HR (95%CI)
P value
HR (95%CI)
P value
Liver cancer
≥ 50 yr82792341035.37Ref.Ref.
< 50 yr1703914918.610.65 (0.61-0.68)< 0.0010.64 (0.61-0.68)< 0.001
Baseline comorbidity
HBV2049755227.130.81 (0.77-0.85)< 0.0010.76 (0.72-0.80)< 0.001
HCV831351323.650.75 (0.70-0.81)< 0.0010.72 (0.67-0.78)< 0.001
Unspecified chronic hepatitis584222426.250.90 (0.83-0.98)0.0150.96 (0.88-1.05)0.349
Alcoholic liver disease16544936.721.04 (0.89-1.21)0.6401.07 (0.91-1.25)0.408
Cirrhosis3186992432.101.01 (0.97-1.05)0.7391.18 (1.13-1.24)< 0.001
Biliary stone955273034.981.08 (1.01-1.15)0.0240.98 (0.91-1.05)0.562
Cholecystitis416216219.250.70 (0.63-0.77)< 0.0010.71 (0.64-0.78)< 0.001
Cholangitis68798969.451.76 (1.63-1.91)< 0.0011.77 (1.63-1.92)< 0.001
Table 6 Survival rates of different follow-up durations between primary liver cancer patients with and without menopause
Follow-up duration
Survival rate (%)
P value
≥ 50 yr< 50 yr
≤ 0.564.1672.44< 0.001
≤ 151.6660.57< 0.001
≤ 331.2842.92< 0.001
≤ 521.8337.02< 0.001